Taipei Exchange - Delayed Quote TWD

Diamond Biotechnology Co., Ltd (6815.TWO)

65.20
+2.20
+(3.49%)
At close: 2:58:52 PM GMT+8
Loading Chart for 6815.TWO
  • Previous Close 63.00
  • Open 63.90
  • Bid 64.40 x --
  • Ask 64.50 x --
  • Day's Range 62.80 - 66.80
  • 52 Week Range 44.65 - 113.95
  • Volume 191,275
  • Avg. Volume 123,245
  • Market Cap (intraday) 2.19B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) 28.10
  • EPS (TTM) 2.32
  • Earnings Date --
  • Forward Dividend & Yield 0.16 (0.27%)
  • Ex-Dividend Date Aug 5, 2024
  • 1y Target Est --

Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment. Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.

www.diamond-biotechnology.cc

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6815.TWO

View More

Performance Overview: 6815.TWO

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6815.TWO
16.20%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.44%

1-Year Return

6815.TWO
22.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.80%

3-Year Return

6815.TWO
138.55%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.58%

5-Year Return

6815.TWO
186.50%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
102.05%

Compare To: 6815.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6815.TWO

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    2.12B

  • Enterprise Value

    2.12B

  • Trailing P/E

    28.12

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.68

  • Price/Book (mrq)

    3.40

  • Enterprise Value/Revenue

    2.76

  • Enterprise Value/EBITDA

    16.17

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.47%

  • Return on Assets (ttm)

    6.78%

  • Return on Equity (ttm)

    14.22%

  • Revenue (ttm)

    707.54M

  • Net Income Avi to Common (ttm)

    66.97M

  • Diluted EPS (ttm)

    2.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    224.14M

  • Total Debt/Equity (mrq)

    49.35%

  • Levered Free Cash Flow (ttm)

    -70.47M

Research Analysis: 6815.TWO

View More

Company Insights: 6815.TWO

Research Reports: 6815.TWO

View More

People Also Watch